Suppression and transient induction of lymphokines in cancer patients after administration of polyethylene glycolated interleukin-2

Yihshing Shih, Michael W. Konrad, M. Kim Warren, Anne Childs, Carolyn Paradise, Frederick J Meyers, Eric S. Groves

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

Polyethylene glycolated (pegylated) interleukin-2 (PEG IL-2) was administered as a weekly i.v. bolus to patients with metastatic cancer in a phase-I trial. Efficacy, toxicity and pharmacokinetics have been described previously. To explore mechanism of IL-2 action and discover predictors of efficacy, the levels of several lymphokines were measured in pharmacokinetic serum samples. IL-1β and IL-6 were elevated in many patients before PEG IL-2 administration, forming a continuous, log-normal distribution among patients. The levels of the two lymphokines were strongly correlated. However, no significant correlation could be found between these levels, clinical chemistry, or tumor regression seen after PEG IL-2 administration. Three hours after PEG IL-2 administration, IL-1β and IL-6 levels, if elevated, fell to normal. In all patients, independent of initial levels, IL-6 and IFN-γ, but not IL-1β, increased 4 to 6 h after the injection and then fell rapidly, even though PEG IL-2 levels were high and often changed only slightly during this period. This suggests an active shut down of lymphokine synthesis, or an increase in elimination rate. After the fourth administration of PEG IL-2, the peak level of IFN-γ was 2 to 20 times higher than after the first, while the peak level of IL-6 did not change in a consistent direction. Responding patients had typical peak levels of IL-6 and IFN-γ. Low levels of TNF and IL-4 were occasionally seen before and after PEG IL-2 administration, but no consistent pattern was evident.

Original languageEnglish (US)
Pages (from-to)727-733
Number of pages7
JournalEuropean Journal of Immunology
Volume22
Issue number3
StatePublished - Mar 1992

Fingerprint

Lymphokines
Polyethylene
Interleukin-2
Interleukin-6
Neoplasms
Interleukin-1
Pharmacokinetics
Clinical Chemistry
Normal Distribution
Interleukin-4
Injections
Serum

ASJC Scopus subject areas

  • Immunology

Cite this

Suppression and transient induction of lymphokines in cancer patients after administration of polyethylene glycolated interleukin-2. / Shih, Yihshing; Konrad, Michael W.; Warren, M. Kim; Childs, Anne; Paradise, Carolyn; Meyers, Frederick J; Groves, Eric S.

In: European Journal of Immunology, Vol. 22, No. 3, 03.1992, p. 727-733.

Research output: Contribution to journalArticle

Shih, Yihshing ; Konrad, Michael W. ; Warren, M. Kim ; Childs, Anne ; Paradise, Carolyn ; Meyers, Frederick J ; Groves, Eric S. / Suppression and transient induction of lymphokines in cancer patients after administration of polyethylene glycolated interleukin-2. In: European Journal of Immunology. 1992 ; Vol. 22, No. 3. pp. 727-733.
@article{5c400ae106b0408084d572a68ba804f1,
title = "Suppression and transient induction of lymphokines in cancer patients after administration of polyethylene glycolated interleukin-2",
abstract = "Polyethylene glycolated (pegylated) interleukin-2 (PEG IL-2) was administered as a weekly i.v. bolus to patients with metastatic cancer in a phase-I trial. Efficacy, toxicity and pharmacokinetics have been described previously. To explore mechanism of IL-2 action and discover predictors of efficacy, the levels of several lymphokines were measured in pharmacokinetic serum samples. IL-1β and IL-6 were elevated in many patients before PEG IL-2 administration, forming a continuous, log-normal distribution among patients. The levels of the two lymphokines were strongly correlated. However, no significant correlation could be found between these levels, clinical chemistry, or tumor regression seen after PEG IL-2 administration. Three hours after PEG IL-2 administration, IL-1β and IL-6 levels, if elevated, fell to normal. In all patients, independent of initial levels, IL-6 and IFN-γ, but not IL-1β, increased 4 to 6 h after the injection and then fell rapidly, even though PEG IL-2 levels were high and often changed only slightly during this period. This suggests an active shut down of lymphokine synthesis, or an increase in elimination rate. After the fourth administration of PEG IL-2, the peak level of IFN-γ was 2 to 20 times higher than after the first, while the peak level of IL-6 did not change in a consistent direction. Responding patients had typical peak levels of IL-6 and IFN-γ. Low levels of TNF and IL-4 were occasionally seen before and after PEG IL-2 administration, but no consistent pattern was evident.",
author = "Yihshing Shih and Konrad, {Michael W.} and Warren, {M. Kim} and Anne Childs and Carolyn Paradise and Meyers, {Frederick J} and Groves, {Eric S.}",
year = "1992",
month = "3",
language = "English (US)",
volume = "22",
pages = "727--733",
journal = "European Journal of Immunology",
issn = "0014-2980",
publisher = "Wiley-VCH Verlag",
number = "3",

}

TY - JOUR

T1 - Suppression and transient induction of lymphokines in cancer patients after administration of polyethylene glycolated interleukin-2

AU - Shih, Yihshing

AU - Konrad, Michael W.

AU - Warren, M. Kim

AU - Childs, Anne

AU - Paradise, Carolyn

AU - Meyers, Frederick J

AU - Groves, Eric S.

PY - 1992/3

Y1 - 1992/3

N2 - Polyethylene glycolated (pegylated) interleukin-2 (PEG IL-2) was administered as a weekly i.v. bolus to patients with metastatic cancer in a phase-I trial. Efficacy, toxicity and pharmacokinetics have been described previously. To explore mechanism of IL-2 action and discover predictors of efficacy, the levels of several lymphokines were measured in pharmacokinetic serum samples. IL-1β and IL-6 were elevated in many patients before PEG IL-2 administration, forming a continuous, log-normal distribution among patients. The levels of the two lymphokines were strongly correlated. However, no significant correlation could be found between these levels, clinical chemistry, or tumor regression seen after PEG IL-2 administration. Three hours after PEG IL-2 administration, IL-1β and IL-6 levels, if elevated, fell to normal. In all patients, independent of initial levels, IL-6 and IFN-γ, but not IL-1β, increased 4 to 6 h after the injection and then fell rapidly, even though PEG IL-2 levels were high and often changed only slightly during this period. This suggests an active shut down of lymphokine synthesis, or an increase in elimination rate. After the fourth administration of PEG IL-2, the peak level of IFN-γ was 2 to 20 times higher than after the first, while the peak level of IL-6 did not change in a consistent direction. Responding patients had typical peak levels of IL-6 and IFN-γ. Low levels of TNF and IL-4 were occasionally seen before and after PEG IL-2 administration, but no consistent pattern was evident.

AB - Polyethylene glycolated (pegylated) interleukin-2 (PEG IL-2) was administered as a weekly i.v. bolus to patients with metastatic cancer in a phase-I trial. Efficacy, toxicity and pharmacokinetics have been described previously. To explore mechanism of IL-2 action and discover predictors of efficacy, the levels of several lymphokines were measured in pharmacokinetic serum samples. IL-1β and IL-6 were elevated in many patients before PEG IL-2 administration, forming a continuous, log-normal distribution among patients. The levels of the two lymphokines were strongly correlated. However, no significant correlation could be found between these levels, clinical chemistry, or tumor regression seen after PEG IL-2 administration. Three hours after PEG IL-2 administration, IL-1β and IL-6 levels, if elevated, fell to normal. In all patients, independent of initial levels, IL-6 and IFN-γ, but not IL-1β, increased 4 to 6 h after the injection and then fell rapidly, even though PEG IL-2 levels were high and often changed only slightly during this period. This suggests an active shut down of lymphokine synthesis, or an increase in elimination rate. After the fourth administration of PEG IL-2, the peak level of IFN-γ was 2 to 20 times higher than after the first, while the peak level of IL-6 did not change in a consistent direction. Responding patients had typical peak levels of IL-6 and IFN-γ. Low levels of TNF and IL-4 were occasionally seen before and after PEG IL-2 administration, but no consistent pattern was evident.

UR - http://www.scopus.com/inward/record.url?scp=0026549742&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0026549742&partnerID=8YFLogxK

M3 - Article

C2 - 1547819

AN - SCOPUS:0026549742

VL - 22

SP - 727

EP - 733

JO - European Journal of Immunology

JF - European Journal of Immunology

SN - 0014-2980

IS - 3

ER -